- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07948980
Platelet Dysfunction in Patients With Bleeding Disorder of Unknown Cause (TARGET-BDUC)
Platelet Dysfunction in Bleeding Disorder of Unknown Cause: Novel Diagnostic and Therapeutic Targets of Platelet Dysfunction in Patients With Bleeding Disorder of Unknown Cause - The TARGET-BDUC Study
Bleeding disorder of unknown cause (BDUC) affects people who experience excessive bleeding despite normal routine laboratory tests. Undetected platelet dysfunction may contribute to their bleeding symptoms.
The TARGET-BDUC study aims to investigate platelet function, particularly the formation of procoagulant platelets, and identify underlying mechanisms and potential diagnostic biomarkers.
The study will include 100 patients with BDUC and 30 healthy controls. Advanced platelet function testing, imaging, and proteomic and lipidomic analyses will be performed.
The findings may improve the diagnosis of BDUC and help identify patients who could benefit from targeted treatment.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
This single-center observational study will recruit 100 patients with bleeding disorder of unknown cause (BDUC) from the Vienna Bleeding Biobank (VIBB) at the Medical University of Vienna and 30 age- and sex-matched healthy controls from the Vienna Bleeding Study (VIBS).
Patients with BDUC will have a clinically relevant bleeding phenotype despite normal conventional hemostatic testing, including light transmission aggregometry, and at least one prolonged PFA-100 closure time.
All participants will undergo comprehensive platelet function testing. For detailed mechanistic and multi-omics analyses, 30 BDUC patients with reduced procoagulant platelet formation, 30 BDUC patients with normal procoagulant platelet formation, and 30 healthy controls will be selected.
An exploratory substudy will assess platelet function before and after desmopressin (DDAVP) administration in 10 patients with BDUC and 5 comparison participants receiving DDAVP as part of routine clinical care.
Beschrijving
Inclusion Criteria:
Patients with bleeding disorder of unknown cause (BDUC):
- Age ≥16 years.
- Diagnosis of BDUC following comprehensive hemostatic evaluation without identification of a specific bleeding disorder.
- Abnormal ISTH Bleeding Assessment Tool (ISTH-BAT) score (≥4 in men or ≥6 in women).
- Normal light transmission aggregometry (LTA).
- Prolonged PFA-100 closure time in at least one cartridge (collagen/epinephrine or collagen/ADP).
- Written informed consent.
Healthy controls:
- Age ≥16 years.
- No history of abnormal bleeding or thrombosis.
- Age- and sex-matched to the BDUC study population.
- Written informed consent.
Exclusion Criteria:
- Pregnancy.
- Recent surgery or infection.
- Active malignancy.
- Thrombocytopenia (platelet count <100 × 10⁹/L).
- Liver dysfunction (prothrombin time activity <75%).
- Renal impairment (eGFR <60 mL/min/1.73 m²).
- Use of anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), or other medications affecting platelet function within 10 days before blood sampling.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Procoagulant Platelet Formation in Patients With BDUC Compared With Healthy Controls
Tijdsspanne: At baseline (single blood sample collected at enrollment; no follow-up assessment).
|
Procoagulant platelet formation will be quantified by flow cytometry following dual platelet stimulation with TRAP-6 and CRP-XL. Procoagulant platelets will be identified by simultaneous CD62P and lactadherin positivity, indicating platelet activation and phosphatidylserine exposure. The percentage of procoagulant platelets will be compared between patients with bleeding disorder of unknown cause (BDUC) and healthy controls to identify impaired procoagulant platelet responses. |
At baseline (single blood sample collected at enrollment; no follow-up assessment).
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- KLP1389626
- KLP1389626 (Ander subsidie-/financieringsnummer: Austrian Science Fund (FWF))
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .